Search | Clinical Trials Finder

Conditions: Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more

Conditions: Metabolic Dysfunction-associated Steatohepatitis
Interventions: Placebo, ECC4703, ECC0509; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 68
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 58 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), MetALD
Interventions: Not listed
Lead sponsor: HRI-MAIL-NIT; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 4 more

Conditions: MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Resmetirom; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 74
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 60 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Interventions: ALN-CIDEB, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Chandler, Arizona • Tucson, Arizona

Conditions: Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions: BI 770371, Placebo for BI 770371; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Coronado, California • Montclair, California + 8 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Pegozafermin, Placebo; Biological · Other
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 154
States / cities: Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more

Conditions: Aneurysm, Ruptured, Vasospasm, Intracranial, Delayed Cerebral Ischemia, Blood Brain Barrier Defect
Interventions: Minocyclin; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
Interventions: Not listed
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Timeline: 2025
U.S. locations: 1
States / cities: Lady Lake, Florida

Conditions: Ruptured Aneurysm, Memory Deficits, Subarachnoid Hemorrhage
Interventions: Lumosity, Crossword puzzle; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Rezdiffra, Resmetirom, ACTOS/pioglitazone, FARXIGA/dapagliflozin; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 16
States / cities: Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 12 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis
Interventions: Survodutide, Placebo matching survodutide; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 126
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more

Conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Placebo (PB); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Glendale, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions: ESG + lifestyle modification, Lifestyle modification; Device · Behavioral
Lead sponsor: Pichamol Jirapinyo, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Morgantown, West Virginia

Conditions: NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
Interventions: Digoxin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions: LY3849891, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Orange, California • Rialto, California + 8 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Miricorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Interventions: TVB-2640, Placebo; Drug · Other
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 103
States / cities: Huntsville, Alabama • Madison, Alabama • Sun City, Arizona + 80 more

Conditions: Hypertension, Adherence, Medication
Interventions: Medication Adherence Problem Solving for Hypertension; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Low-back Pain, Hip Impairments, Hip-spine Syndrome, Osteoarthritis
Interventions: Hip-focused rehabilitation intervention, Spine-focused rehabilitation intervention; Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 60 Years to 85 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Newark, Delaware • Durham, North Carolina • Pittsburgh, Pennsylvania

Conditions: Liver Cancer, Adult, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Obesity and Overweight
Interventions: Time-restricted eating plus healthy diet; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Resmetirom, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 12 more

Search by objective public record fields.

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Assessment of Non-Invasive Testing in Major Liver-Related Outcomes

Study of Resmetirom in Children and Adolescents With MASH

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)

Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.

Memory Training in Aneurysmal Subarachnoid Hemorrhage Patients

Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Digoxin In NASH (CODIN)

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Testing Feasibility of Medication Adherence Problem Solving for Hypertension

Manual Therapy and Strengthening for the Hip in Older Adults With Chronic Low Back Pain

Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH